All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Jazz Pharmaceuticals, Kura Oncology, Roche and Syndax and has been supported through a grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Bookmark this article
On 28th April 2017, the U.S. Food and Drug Administration (FDA) granted approval to midostaurin (Rydapt) for the treatment of newly diagnosed Acute Myeloid Leukemia (AML) who are Fms Like Tyrosine Kinase 3 (FLT3) mutated-positive (FLT3+), as detected by an FDA-approved test, in combination with standard cytarabine and daunorubicin and cytarabine consolidation.1
In addition, the FDA approved a companion diagnostic, the LeukoStrat CDx FLT3 Mutation Assay for use with midostaurin to test patients with AML for the FLT3 mutations.
This approval for midostaurin, a FLT3 inhibitor, is based on results from the phase 3 RATIFY trial (NCT00651261), which as a randomized trial in 717 newly diagnosed FLT3+ AML patients. In this study, patients were randomly assigned to receive either placebo or midostaurin 50 mg orally twice daily on days 8–21 of each cycle of induction and consolidation chemotherapy followed by continuous daily midostaurin for up to 12 cycles.
The approved regimens of midostaurin in AML is 50 mg twice daily with food on days 8 to 21 of each cycle of induction and consolidation chemotherapy followed by 50 mg with food as a single agent for up to 12 months.
Your opinion matters
Subscribe to get the best content related to AML delivered to your inbox